APPENDIX
DEFINITIONS
ACTION REGISTRY®–GWTG™
Overall Acute Myocardial Infarction (AMI) Performance Composite
The proportion of performance measure opportunities that were met among eligible
opportunities, which includes all of the following eleven acute and discharge performance
measures: Aspirin at Arrival, Evaluation of LV Systolic Function, Reperfusion Therapy [STElevation Myocardial Infarction (STEMI) only], Time to Fibrinolytics (STEMI only), Time to
Primary Percutaneous Coronary Intervention (PCI) (STEMI only), Aspirin at Discharge, Beta
Blocker at Discharge, Angiotensin Converting Enzyme Inhibitors (ACE-I) or Angiotensin
Receptor Blocker (ARB) for Left Ventricular Systolic Dysfunction [LVSD; defined as chart
documentation of a left ventricular ejection fraction (LVEF) less than 40% or a narrative
description of left ventricular systolic function consistent with “Moderately” or “Severely”
reduced systolic dysfunction] at Discharge, Statin at Discharge, Adult Smoking Cessation
Advice, and Cardiac Rehab Referral.
Overall Defect Free Care
The proportion of patients that receive "perfect care" based upon their eligibility for each
performance measure. If a patient fails to receive even one therapy for which he or she is
eligible, that patient fails to meet the "defect-free" criteria and will be removed from the
numerator. That patient will still be included in the denominator however.
ST-Elevation Myocardial Infarction (STEMI) Performance Composite
The proportion of performance measure opportunities that were met among eligible
opportunities, which includes all of the following eleven acute and discharge performance
measures for STEMI patients: Aspirin at Arrival. Evaluation of LV Systolic Function,
Reperfusion Therapy (STEMI only), Time to Fibrinolytics <30 minutes (STEMI only), Time to
Primary PCI < 90 minutes (STEMI only), Aspirin at Discharge, Beta Blocker at Discharge,
ACE-I or ARB for LVSD at Discharge, Statin at Discharge, Adult Smoking Cessation Advice,
and Cardiac Rehab Referral.
Non–ST-Elevation Myocardial Infarction (NSTEMI) Performance Composite
The proportion of performance measure opportunities that were met among eligible
opportunities, which includes all of the following eight acute and discharge performance
measures for NSTEMI patients: Aspirin at Arrival, Evaluation of LV Systolic Function, Aspirin
at Discharge, Beta Blocker at Discharge, ACE-I or ARB for LVSD at Discharge, Statin at
Discharge, Adult Smoking Cessation Advice, and Cardiac Rehab Referral.
Acute AMI Performance Composite
The proportion of AMI patients with perfect adherence to the performance measures among all
eligible care opportunities for those patients, which includes all of the following five acute
composite performance measures for all AMI patients: Aspirin at Arrival, Evaluation of LV
Systolic Function, Reperfusion Therapy (STEMI only), Time to Fibrinolytics < 30 minutes
(STEMI only), and Time to Primary PCI < 90 minutes (STEMI only).
Discharge AMI Performance Composite
The proportion of performance measure opportunities that were met among eligible
opportunities, which includes all of the following six discharge performance measures for all
AMI patients: Aspirin at Discharge, Beta Blocker at Discharge, ACE-I or ARB for LVSD at
Discharge, Statin at Discharge, Adult Smoking Cessation Advice, and Cardiac Rehab Referral.
Median Door-to-Balloon (D2B) Time for Non-Transferred Patients (minutes)
Median time in minutes from hospital arrival to primary PCI for STEMI patients.
Median Door-to-Balloon (D2B) Time for Transferred Patients (minutes)
Median time in minutes from arrival at STEMI referring facility to primary PCI at STEMI
receiving facility among patients transferred for a primary PCI.
Median Door-in-Door-Out Time for Transferred Patients (minutes)
Median time in minutes from ED arrival at referral facility to ED discharge at referral facility
among patients transferred for a primary PCI.
Electrocardiogram (ECG) w/in 10 Minutes of Arrival
Proportion of AMI patients that received an ECG within 10 minute of arrival at participating
hospital.
Acute Adenosine Diphosphate (ADP) Receptor Inhibitor Therapy Among STEMI Patients
Proportion of STEMI patients prescribed ADP Receptor Inhibitors 24 hours prior to or after 1st
hospital arrival.
Acute Anticoagulant Agent Among NSTEMI Patients
Proportion of NSTEMI patients prescribed unfractionated heparin, enoxaparin, bivalirudin or
fondaparinux 24 hours prior to or after 1st hospital arrival.
Excessive Initial Unfractionated Heparin (UFH) Dose, Excessive Initial Enoxaparin Dose
(LMWH), or Excessive Initial Glycoprotein (GP) IIb/IIIa Inhibitor Therapy
Proportion of AMI patients that received: an initial bolus dose of UFH >70 units per kilogram
OR infusion > 15 units per kilogram per hour (UFH); an initial dose of subcutaneous Enoxaparin
>1.05 mg per kilogram [low molecular weight heparin (LMWH)]; GP IIb/IIIa [full dose of
Tirofiban if Creatinine Clearance Calculator (CrCL) <30 cc/min and/or dialysis = yes or full
dose of Eptifibatide if CrCL <50 cc//min and /or dialysis = yes].
Reperfusion Use
Proportion of STEMI patients with a time from: hospital arrival (or subsequent ECG if ST
elevation first noted on subsequent ECG) to primary PCI <= 90 minutes (D2B <90 min - NonTransfer In); emergency department arrival at STEMI referral facility to Primary PCI at STEMI
receiving facility <= 90 minutes (D2B <90 min - Transfer In); hospital arrival to receiving
thrombolytic therapy <= 30 minutes [door-to-needle (D2Needle) <30 min – All].
CathPCI REGISTRY®
Median Time to Immediate PCI for STEMI Patients (In Minutes) (D2B)
Median time in minutes from hospital arrival to immediate PCI for STEMI patients. Exclusions:
Patients transferred in from another acute care facility; reason for delay does not equal “none”.
Proportion of STEMI Patients Receiving Immediate PCI w/in 90 minutes (D2B)
The proportion of STEMI patients with a time from hospital arrival (or subsequent ECG if ST
elevation first noted on subsequent ECG) to immediate PCI <=90 minutes. Exclusions: Patients
transferred in from another acute care facility; reason for delay does not equal “none”.
Discharge Medications in PCI Patients
Proportion of patients (without a documented contraindication) with aspirin, statin, and/or beta
blockers prescribed at discharge. Proportion of patients (without a documented contraindication)
with a stent implanted that had a thienopyridine/P2Y12 inhibitor prescribed at discharge.
Patients WITH Acute Coronary Syndrome: Proportion of Evaluated PCI Procedures That Were
Appropriate
The proportion of PCI procedures that were evaluated as “Appropriate”, among patients with
ACS, meaning coronary revascularization is generally acceptable and is a reasonable approach
for the indication and is likely to improve the patients’ health outcomes or survival.
Patients WITH Acute Coronary Syndrome: Proportion of Evaluated PCI Procedures That Were
of Uncertain Appropriateness
The proportion of PCI procedures that were evaluated as “Uncertain”, among patients with ACS,
meaning coronary revascularization may be acceptable and may be a reasonable approach for the
indication. However, some degree of uncertainty exists, implying that more research and/or
patient information is needed to determine whether the procedure would improve patients’ health
outcomes or survival.
Patients WITH Acute Coronary Syndrome: Proportion of Evaluated PCI Procedures That Were
Inappropriate
The proportion of PCI procedures that were evaluated as “Inappropriate”, among patients with
ACS, meaning coronary revascularization is not generally acceptable and is not a reasonable
approach for the indication and is unlikely to improve the patients’ health outcomes or survival.
Patients WITHOUT Acute Coronary Syndrome: Proportion of Evaluated PCI Procedures That
Were Appropriate
The proportion of PCI procedures that were evaluated as “Appropriate”, among patients without
ACS, meaning coronary revascularization is generally acceptable and is a reasonable approach
for the indication and is likely to improve the patients’ health outcomes or survival.
Patients WITHOUT Acute Coronary Syndrome: Proportion of Evaluated PCI Procedures That
Were of Uncertain Appropriateness
The proportion of PCI procedures that were evaluated as “Uncertain”, among patients without
ACS, meaning coronary revascularization may be acceptable and may be a reasonable approach
for the indication. However, some degree of uncertainty exists, implying that more research
and/or patient information is needed to determine whether the procedure would improve patients’
health outcomes or survival.
Patients WITHOUT Acute Coronary Syndrome: Proportion of Evaluated PCI Procedures That
Were Inappropriate
The proportion of PCI procedures that were evaluated as “Inappropriate”, among patients
without ACS, meaning coronary revascularization is not generally acceptable and is not a
reasonable approach for the indication and is unlikely to improve the patients’ health outcomes
or survival.
PCI In-hospital Risk Adjusted Mortality
PCI in-hospital risk adjusted mortality rate for patients with (1) STEMI and (2) other diagnoses
(not STEMI), adjusted using the NCDR® risk adjustment model.
Proportion of PCI Procedures with Acute Kidney Injury
The proportion of patients who had a rise of serum creatinine of > 50% over the pre-procedure
baseline (excluding patients on dialysis preprocedure). Inclusions: >= 90% of patients with a pre
and post creatinine coded; length of stay >=1 day.
Proportion of PCI Procedures with Post Procedure Stroke
The proportion of patients with stroke post procedure; excludes patients with CABG.
Proportion of PCI Procedures with Transfusion of Whole Blood or RBCs
Proportion of patients who received a transfusion of whole blood or red blood cells after a PCI
procedure. Inclusion: Patients with a pre-procedure hemoglobin >8 g/dL and patients with no
CABG, and no other major surgery during the same admission.
Proportion of PCI Procedures with Vascular Access Site Injury Requiring Treatment or Major
Bleeding
Proportion of patients (excluding CABG or other surgery during same admission) with major
access site related injury requiring treatment or major bleeding.
CARE REGISTRY®
Procedures with Patients at High Surgical Risk
The proportion of procedures with patients with at least one condition that qualifies the patient to
be at high surgical risk as defined by the ACCF/SCAI/SVMB/SIR/ASITN 2007 Clinical Expert
Consensus Document on Carotid Stenting.
Any Follow-up Performed Within 30 Days Following the Procedure
The proportion of patients who had any follow-up performed within 30 days following the
procedure.
Incidence of Death or Stroke for Symptomatic and Asymptomatic Patients
The proportion of symptomatic and asymptomatic patients who die, or experience a new stroke
from the time of the CAS or CEA procedure through discharge.
ICD REGISTRY®
CMS Primary Prevention
The use of ICDs in individuals who are at risk for but have not yet had an episode of sustained
ventricular tachycardia, ventricular fibrillation, or resuscitated cardiac arrest and being billed to
Medicare.
Non-CMS Primary Prevention
The use of ICDs in individuals who are at risk for but have not yet had an episode of sustained
ventricular tachycardia, ventricular fibrillation, or resuscitated cardiac arrest and being billed to
any insurance other than Medicare.
All Secondary Prevention
Refers to an ICD indication for patients who have survived one or more cardiac arrests or
sustained ventricular tachycardia. Patients with cardiac conditions associated with a high risk of
sudden death who have unexplained syncope that is likely to be due to ventricular arrhythmias
are considered to have a secondary indication.
PINNACLE REGISTRY®
Coronary Artery Disease
Antiplatelet Therapy
Percentage of eligible patients who were prescribed antiplatelet therapy.
Drug Therapy for Lowering LDL-Cholesterol
Percentage of eligible patients who were prescribed lipid-lowering therapy (based on current
ACC/AHA guidelines).
Beta-Blocker Therapy - Prior Myocardial Infarction
Percentage of eligible CAD patients with prior MI who were prescribed beta-blocker therapy.
ACE Inhibitor or ARB Therapy
Percentage of eligible CAD patients who also have diabetes and/or LVSD (LVEF <40% or a
narrative description of left ventricular systolic function consistent with “Moderately” or
“Severely” reduced systolic dysfunction) who were prescribed ACE inhibitor or ARB therapy.
Heart Failure
Beta-Blocker Therapy
Percentage of eligible HF patients who also have Left Ventricular Systolic Dysfunction (LVEF
<40% or a “Moderately” or “Severely” Reduced” Qualitative Assessment) who were prescribed
beta-blocker therapy.
ACE Inhibitor or ARB for Patients with Heart Failure Who Have LVSD
Percentage of eligible HF patients who also have LVSD (LVEF <40% or a narrative description
of left ventricular systolic function consistent with “Moderately” or “Severely” reduced systolic
dysfunction) who were prescribed ACE inhibitor or ARB therapy.
Atrial Fibrilla APPENDIX - DEFINITIONS
ACTION REGISTRY®–GWTG™
Overall Acute Myocardial Infarction (AMI) Performance Composite
The proportion of performance measure opportunities that were met among eligible
opportunities, which includes all of the following eleven acute and discharge performance
measures: Aspirin at Arrival, Evaluation of LV Systolic Function, Reperfusion Therapy [STElevation Myocardial Infarction (STEMI) only], Time to Fibrinolytics (STEMI only), Time to
Primary Percutaneous Coronary Intervention (PCI) (STEMI only), Aspirin at Discharge, Beta
Blocker at Discharge, Angiotensin Converting Enzyme Inhibitors (ACE-I) or Angiotensin
Receptor Blocker (ARB) for Left Ventricular Systolic Dysfunction [LVSD; defined as chart
documentation of a left ventricular ejection fraction (LVEF) less than 40% or a narrative
description of left ventricular systolic function consistent with “Moderately” or “Severely”
reduced systolic dysfunction] at Discharge, Statin at Discharge, Adult Smoking Cessation
Advice, and Cardiac Rehab Referral.
Overall Defect Free Care
The proportion of patients that receive "perfect care" based upon their eligibility for each
performance measure. If a patient fails to receive even one therapy for which he or she is
eligible, that patient fails to meet the "defect-free" criteria and will be removed from the
numerator. That patient will still be included in the denominator however.
ST-Elevation Myocardial Infarction (STEMI) Performance Composite
The proportion of performance measure opportunities that were met among eligible
opportunities, which includes all of the following eleven acute and discharge performance
measures for STEMI patients: Aspirin at Arrival. Evaluation of LV Systolic Function,
Reperfusion Therapy (STEMI only), Time to Fibrinolytics <30 minutes (STEMI only), Time to
Primary PCI < 90 minutes (STEMI only), Aspirin at Discharge, Beta Blocker at Discharge,
ACE-I or ARB for LVSD at Discharge, Statin at Discharge, Adult Smoking Cessation Advice,
and Cardiac Rehab Referral.
Non–ST-Elevation Myocardial Infarction (NSTEMI) Performance Composite
The proportion of performance measure opportunities that were met among eligible
opportunities, which includes all of the following eight acute and discharge performance
measures for NSTEMI patients: Aspirin at Arrival, Evaluation of LV Systolic Function, Aspirin
at Discharge, Beta Blocker at Discharge, ACE-I or ARB for LVSD at Discharge, Statin at
Discharge, Adult Smoking Cessation Advice, and Cardiac Rehab Referral.
Acute AMI Performance Composite
The proportion of AMI patients with perfect adherence to the performance measures among all
eligible care opportunities for those patients, which includes all of the following five acute
composite performance measures for all AMI patients: Aspirin at Arrival, Evaluation of LV
Systolic Function, Reperfusion Therapy (STEMI only), Time to Fibrinolytics < 30 minutes
(STEMI only), and Time to Primary PCI < 90 minutes (STEMI only).
Discharge AMI Performance Composite
The proportion of performance measure opportunities that were met among eligible
opportunities, which includes all of the following six discharge performance measures for all
AMI patients: Aspirin at Discharge, Beta Blocker at Discharge, ACE-I or ARB for LVSD at
Discharge, Statin at Discharge, Adult Smoking Cessation Advice, and Cardiac Rehab Referral.
Median Door-to-Balloon (D2B) Time for Non-Transferred Patients (minutes)
Median time in minutes from hospital arrival to primary PCI for STEMI patients.
Median Door-to-Balloon (D2B) Time for Transferred Patients (minutes)
Median time in minutes from arrival at STEMI referring facility to primary PCI at STEMI
receiving facility among patients transferred for a primary PCI.
Median Door-in-Door-Out Time for Transferred Patients (minutes)
Median time in minutes from ED arrival at referral facility to ED discharge at referral facility
among patients transferred for a primary PCI.
Electrocardiogram (ECG) w/in 10 Minutes of Arrival
Proportion of AMI patients that received an ECG within 10 minute of arrival at participating
hospital.
Acute Adenosine Diphosphate (ADP) Receptor Inhibitor Therapy Among STEMI Patients
Proportion of STEMI patients prescribed ADP Receptor Inhibitors 24 hours prior to or after 1st
hospital arrival.
Acute Anticoagulant Agent Among NSTEMI Patients
Proportion of NSTEMI patients prescribed unfractionated heparin, enoxaparin, bivalirudin or
fondaparinux 24 hours prior to or after 1st hospital arrival.
Excessive Initial Unfractionated Heparin (UFH) Dose, Excessive Initial Enoxaparin Dose
(LMWH), or Excessive Initial Glycoprotein (GP) IIb/IIIa Inhibitor Therapy
Proportion of AMI patients that received: an initial bolus dose of UFH >70 units per kilogram
OR infusion > 15 units per kilogram per hour (UFH); an initial dose of subcutaneous Enoxaparin
>1.05 mg per kilogram [low molecular weight heparin (LMWH)]; GP IIb/IIIa [full dose of
Tirofiban if Creatinine Clearance Calculator (CrCL) <30 cc/min and/or dialysis = yes or full
dose of Eptifibatide if CrCL <50 cc//min and /or dialysis = yes]. Cleveland Clinic Foundation,
Cleveland, Ohio
Reperfusion Use
Proportion of STEMI patients with a time from: hospital arrival (or subsequent ECG if ST
elevation first noted on subsequent ECG) to primary PCI <= 90 minutes (D2B <90 min - NonTransfer In); emergency department arrival at STEMI referral facility to Primary PCI at STEMI
receiving facility <= 90 minutes (D2B <90 min - Transfer In); hospital arrival to receiving
thrombolytic therapy <= 30 minutes [door-to-needle (D2Needle) <30 min – All].
CathPCI REGISTRY®
Median Time to Immediate PCI for STEMI Patients (In Minutes) (D2B)
Median time in minutes from hospital arrival to immediate PCI for STEMI patients. Exclusions:
Patients transferred in from another acute care facility; reason for delay does not equal “none”.
Proportion of STEMI Patients Receiving Immediate PCI w/in 90 minutes (D2B)
The proportion of STEMI patients with a time from hospital arrival (or subsequent ECG if ST
elevation first noted on subsequent ECG) to immediate PCI <=90 minutes. Exclusions: Patients
transferred in from another acute care facility; reason for delay does not equal “none”.
Discharge Medications in PCI Patients
Proportion of patients (without a documented contraindication) with aspirin, statin, and/or beta
blockers prescribed at discharge. Proportion of patients (without a documented contraindication)
with a stent implanted that had a thienopyridine/P2Y12 inhibitor prescribed at discharge.
Patients WITH Acute Coronary Syndrome: Proportion of Evaluated PCI Procedures That Were
Appropriate
The proportion of PCI procedures that were evaluated as “Appropriate”, among patients with
ACS, meaning coronary revascularization is generally acceptable and is a reasonable approach
for the indication and is likely to improve the patients’ health outcomes or survival.
Patients WITH Acute Coronary Syndrome: Proportion of Evaluated PCI Procedures That Were
of Uncertain Appropriateness
The proportion of PCI procedures that were evaluated as “Uncertain”, among patients with ACS,
meaning coronary revascularization may be acceptable and may be a reasonable approach for the
indication. However, some degree of uncertainty exists, implying that more research and/or
patient information is needed to determine whether the procedure would improve patients’ health
outcomes or survival.
Patients WITH Acute Coronary Syndrome: Proportion of Evaluated PCI Procedures That Were
Inappropriate
The proportion of PCI procedures that were evaluated as “Inappropriate”, among patients with
ACS, meaning coronary revascularization is not generally acceptable and is not a reasonable
approach for the indication and is unlikely to improve the patients’ health outcomes or survival.
Patients WITHOUT Acute Coronary Syndrome: Proportion of Evaluated PCI Procedures That
Were Appropriate
The proportion of PCI procedures that were evaluated as “Appropriate”, among patients without
ACS, meaning coronary revascularization is generally acceptable and is a reasonable approach
for the indication and is likely to improve the patients’ health outcomes or survival.
Patients WITHOUT Acute Coronary Syndrome: Proportion of Evaluated PCI Procedures That
Were of Uncertain Appropriateness
The proportion of PCI procedures that were evaluated as “Uncertain”, among patients without
ACS, meaning coronary revascularization may be acceptable and may be a reasonable approach
for the indication. However, some degree of uncertainty exists, implying that more research
and/or patient information is needed to determine whether the procedure would improve patients’
health outcomes or survival.
Patients WITHOUT Acute Coronary Syndrome: Proportion of Evaluated PCI Procedures That
Were Inappropriate
The proportion of PCI procedures that were evaluated as “Inappropriate”, among patients
without ACS, meaning coronary revascularization is not generally acceptable and is not a
reasonable approach for the indication and is unlikely to improve the patients’ health outcomes
or survival.
PCI In-hospital Risk Adjusted Mortality
PCI in-hospital risk adjusted mortality rate for patients with (1) STEMI and (2) other diagnoses
(not STEMI), adjusted using the NCDR® risk adjustment model.
Proportion of PCI Procedures with Acute Kidney Injury
The proportion of patients who had a rise of serum creatinine of > 50% over the pre-procedure
baseline (excluding patients on dialysis preprocedure). Inclusions: >= 90% of patients with a pre
and post creatinine coded; length of stay >=1 day.
Proportion of PCI Procedures with Post Procedure Stroke
The proportion of patients with stroke post procedure; excludes patients with CABG.
Proportion of PCI Procedures with Transfusion of Whole Blood or RBCs
Proportion of patients who received a transfusion of whole blood or red blood cells after a PCI
procedure. Inclusion: Patients with a pre-procedure hemoglobin >8 g/dL and patients with no
CABG, and no other major surgery during the same admission.
Proportion of PCI Procedures with Vascular Access Site Injury Requiring Treatment or Major
Bleeding
Proportion of patients (excluding CABG or other surgery during same admission) with major
access site related injury requiring treatment or major bleeding.
CARE REGISTRY®
Procedures with Patients at High Surgical Risk
The proportion of procedures with patients with at least one condition that qualifies the patient to
be at high surgical risk as defined by the ACCF/SCAI/SVMB/SIR/ASITN 2007 Clinical Expert
Consensus Document on Carotid Stenting.
Any Follow-up Performed Within 30 Days Following the Procedure
The proportion of patients who had any follow-up performed within 30 days following the
procedure.
Incidence of Death or Stroke for Symptomatic and Asymptomatic Patients
The proportion of symptomatic and asymptomatic patients who die, or experience a new stroke
from the time of the CAS or CEA procedure through discharge.
ICD REGISTRY®
CMS Primary Prevention
The use of ICDs in individuals who are at risk for but have not yet had an episode of sustained
ventricular tachycardia, ventricular fibrillation, or resuscitated cardiac arrest and being billed to
Medicare.
Non-CMS Primary Prevention
The use of ICDs in individuals who are at risk for but have not yet had an episode of sustained
ventricular tachycardia, ventricular fibrillation, or resuscitated cardiac arrest and being billed to
any insurance other than Medicare.
All Secondary Prevention
Refers to an ICD indication for patients who have survived one or more cardiac arrests or
sustained ventricular tachycardia. Patients with cardiac conditions associated with a high risk of
sudden death who have unexplained syncope that is likely to be due to ventricular arrhythmias
are considered to have a secondary indication.
PINNACLE REGISTRY®
Coronary Artery Disease
Antiplatelet Therapy
Percentage of eligible patients who were prescribed antiplatelet therapy.
Drug Therapy for Lowering LDL-Cholesterol
Percentage of eligible patients who were prescribed lipid-lowering therapy (based on current
ACC/AHA guidelines).
Beta-Blocker Therapy - Prior Myocardial Infarction
Percentage of eligible CAD patients with prior MI who were prescribed beta-blocker therapy.
ACE Inhibitor or ARB Therapy
Percentage of eligible CAD patients who also have diabetes and/or LVSD (LVEF <40% or a
narrative description of left ventricular systolic function consistent with “Moderately” or
“Severely” reduced systolic dysfunction) who were prescribed ACE inhibitor or ARB therapy.
Heart Failure
Beta-Blocker Therapy
Percentage of eligible HF patients who also have Left Ventricular Systolic Dysfunction (LVEF
<40% or a “Moderately” or “Severely” Reduced” Qualitative Assessment) who were prescribed
beta-blocker therapy.
ACE Inhibitor or ARB for Patients with Heart Failure Who Have LVSD
Percentage of eligible HF patients who also have LVSD (LVEF <40% or a narrative description
of left ventricular systolic function consistent with “Moderately” or “Severely” reduced systolic
dysfunction) who were prescribed ACE inhibitor or ARB therapy.
Atrial Fibrillation/Flutter
Chronic Anticoagulation Therapy for Atrial Fibrillation/Flutter
Prescription of warfarin for all eligible patients with non-valvular atrial fibrillation or atrial
flutter at high risk for thromboembolism, according to risk stratification and 2006 guideline
recommendations.
Hypertension
Blood Pressure Measurement
Percentage of patient visits with blood pressure measurement recorded among hypertension
patients.
Plan of Care
Percentage of patient visits with either systolic blood pressure >= 140 mmHg or diastolic blood
pressure >= 90 mmHg, with documented plan of care for hypertension among hypertension
patients.
Chronic Anticoagulation Therapy for Atrial Fibrillation/Flutter
Prescription of warfarin for all eligible patients with non-valvular atrial fibrillation or atrial
flutter at high risk for thromboembolism, according to risk stratification and 2006 guideline
recommendations.
Hypertension
Blood Pressure Measurement
Percentage of patient visits with blood pressure measurement recorded among hypertension
patients.
Plan of Care
Percentage of patient visits with either systolic blood pressure >= 140 mmHg or diastolic blood
pressure >= 90 mmHg, with documented plan of care for hypertension among hypertension
patients.